DLBCL Prognosis Calculator (IPI and R-IPI)

Your details

The R-IPI was developed for patients treated with R-CHOP and re-stratifies the original IPI into three groups with better prognostic separation. Use IPI for historical comparison.
Age above 60 at diagnosis is an adverse prognostic factor in both IPI and R-IPI.
Stage III = disease on both sides of the diaphragm; Stage IV = disseminated extranodal disease or bone marrow involvement.
Lactate dehydrogenase (LDH) above the upper limit of the local laboratory reference range is an adverse prognostic factor.
ECOG 0 = fully active; ECOG 1 = restricted but ambulatory; ECOG 2-4 = limited or bed-bound. Score 2-4 is adverse.
Extranodal sites include bone marrow, liver, lung, CNS, skin, gastrointestinal tract, and testes. More than one site is adverse.
Total IPI scoreVery Good
0/ 5

Sum of adverse prognostic factors (0 = best, 5 = worst)

Risk groupVery Good
Estimated overall survival1%
Estimated progression-free survival1%
0 points
Very Good / Low<1Good1-2Good / Low-Int.2-3High-Int. / Poor3-4High / Poor4+

R-IPI score 0 - Very Good risk

  • The R-IPI score is 0 out of 5, placing this case in the Very Good risk group.
  • The estimated 4-year overall survival for this risk group is approximately 94%.
  • The estimated 4-year progression-free survival is approximately 94%.
  • Prognostic indices guide, but do not determine, individual treatment decisions. Clinical context, molecular subtype (GCB vs. ABC), and comorbidities all influence management.

Next stepVery Good risk: standard R-CHOP is typically appropriate. Discuss all options with your oncologist.

 = Powered by OnlyCalculators